David Gregory, a patient advocate with the Amyloidosis Alliance, reflects on how treatment options for hATTR-PN have evolved over time and why staying informed remains key.
Transcript
When I started out with it, there was no treatments. So you were given supportive treatments, which weren’t that good.
And then as time went on, new treatments are becoming available. And they were quite good, the first ones. But actually, as time went on, further new treatments came along.
So, you know, my focus was on to get the best treatment that was around. And then because of the disease, now there are several treatments that you can take. And that’s what I’ve been focused on, getting the most up-to-date one.
